Fig. 1: LUCAT1 is upregulated in CRC tissues.

(A) LUCAT1 had higher expression in CRC samples than in matched normal tissues from TCGA database (colon adenocarcinoma (COAD), Normal=41, tumor=471; rectum adenocarcinoma (READ), Normal=10, tumor=167). (B) The relative expression level of LUCAT1 in kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), COAD, lung adenocarcinoma (LUAD), esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC). (C) LUCAT1 in CRC tissues was upregulated compared with that in adjacent normal tissues, n = 36 (measured by qRT-PCR; GAPDH was used as an internal control). (D) Kaplan–Meier estimated overall survival in patients with high or low LUCAT1 expression, higher LUCAT1 expression with poorer overall survival, p = 0.031. Group cutoff-point: 25% (high) and 75% (low). (E) Kaplan–Meier estimated disease-free survival in patients with high or low LUCAT1 expression, higher LUCAT1 expression with poorer disease-free survival, p = 0.017. Group cutoff points were 25% (high) and 75% (low). (F) LUCAT1 expression in colorectal cancer cell lines (HT29, SW480, HCT116, and SW620) was increased compared to that in NCM460 cells, a normal colon cell line (measured by qRT-PCR; GAPDH was used as an internal control). The results are presented as the mean ± s.d. and are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.